Scandibio Therapeutics AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://scandibio.com
Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients
Phase 2
Terminated
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- ScandiBio Therapeutics AB
- Target Recruit Count
- 100
- Registration Number
- NCT04573153
- Locations
- 🇹🇷
University of Health Sciences Istanbul Ãœmraniye Training and Research Hospital, Istanbul, Turkey
Metabolic Cofactor Supplementation in Obese Patients with Non-Alcoholic Fatty Liver Disease
Phase 2
Completed
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Drug: Metabolic Cofactor Supplementation
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- ScandiBio Therapeutics AB
- Target Recruit Count
- 32
- Registration Number
- NCT04330326
- Locations
- 🇹🇷
Koç University Hospital, Istanbul, Turkey
© Copyright 2025. All Rights Reserved by MedPath